Liver Disease News and Research RSS Feed - Liver Disease News and Research

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.
New HCV therapies cost-effective in specific groups of HCV-infected patients

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients. [More]

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. [More]
Experimental nanoparticle therapy speeds healing of all sorts of wounds

Experimental nanoparticle therapy speeds healing of all sorts of wounds

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology. [More]
Study: HBV exposure increases immune system maturation of infants

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B. [More]
Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease. [More]
LDLT effective for treating patients suffering from acute liver failure

LDLT effective for treating patients suffering from acute liver failure

When patients develop acute liver failure, severe complications arise rapidly after the first signs of liver disease, and patients' health can deteriorate rapidly. New research published in the American Journal of Transplantation indicates that emergency evaluations of living liver donors can be conducted safely to allow acute liver failure patients to undergo transplantation before their condition worsens. [More]
FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

FDA approves CHOLBAM (cholic acid) for treatment of bile acid synthesis disorders

Asklepion Pharmaceuticals, LLC. today announced that the U.S. Food and Drug Administration (FDA) approved CHOLBAM (cholic acid) as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. [More]
Flu vaccine based upon four strains of inactivated influenza enhances flu protection

Flu vaccine based upon four strains of inactivated influenza enhances flu protection

A flu vaccine given just under the surface of the skin that includes four strains of inactivated influenza could be more protective than a similar flu vaccine containing only three strains, Saint Louis University research found. [More]
Study describes the dual role of microRNA during hepatitis C infection

Study describes the dual role of microRNA during hepatitis C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery. [More]
WHO releases first-ever guidance for chronic hepatitis B treatment

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year - most of them in low- and middle-income countries. [More]
Exposure to hormone-disrupting chemicals can cause fatty liver disease, promote obesity

Exposure to hormone-disrupting chemicals can cause fatty liver disease, promote obesity

Exposure to low doses of hormone-disrupting chemicals early in life can alter gene expression in the liver as well as liver function, increasing the susceptibility to obesity and other metabolic diseases in adulthood, a new study finds. [More]
New type of vaccine holds promise for prevention of genital herpes

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide. [More]
FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). [More]
Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Study: Plant compounds can help prevent liver damage during menopause

Study: Plant compounds can help prevent liver damage during menopause

Women going through menopause often struggle with weight gain that results when their estrogen levels drop, and many turn to weight-loss supplements to help them shed those extra pounds. But those supplements may cause an accumulation of fat in the liver and a potentially life-threatening condition called non-alcoholic fatty liver disease. [More]
Scientists detect new molecule that contributes to development of liver fibrosis

Scientists detect new molecule that contributes to development of liver fibrosis

Liver fibrosis, which is the progressive formation of scar tissue in the liver, is a massive medical problem. An estimated ten percent of the population is affected by liver fibrosis or its corresponding later stage, liver cirrhosis. A variety of causes can lead to liver fibrosis, the most widely recognized ones being alcohol consumption and virus-induced chronic liver inflammation. [More]
Betaretrovirus may infect patients with primary biliary cirrhosis

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC). [More]
Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

Researchers at Albert Einstein College of Medicine of Yeshiva University have found a possible clue to why older mothers face a higher risk for having babies born with conditions such as Down syndrome that are characterized by abnormal chromosome numbers. [More]
Advertisement
Advertisement